{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-26-019262","form_type":"8-K","ticker":"TGTX","cik":"0001001316","company_name":"TG THERAPEUTICS, INC.","filed_at":"2026-06-03T11:34:29+00:00","discovered_at":"2026-06-03T11:35:00.284955+00:00","generated_at":"2026-06-03T11:35:08.369688+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"TG Therapeutics reports positive Phase 1 data for subcutaneous BRIUMVI; bioavailability >60% vs IV","bullets":["Mean bioavailability >60% relative to IV; lower bound of 95% CI >55%.","PK modeling predicts non-inferior total drug exposure for quarterly SC dosing (GMR 1.21, lower 90% CI 1.15).","Subcutaneous BRIUMVI well tolerated; injection-site reactions <5%, no new safety signals.","B-cell depletion with SC consistent with IV; supports biologic activity.","Phase 3 fully enrolled; top-line data expected late 2026 or early 2027; potential approval in 2028."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-26-019262","json":"https://secwatch.observer/filing/0001437749-26-019262.json","markdown":"https://secwatch.observer/filing/0001437749-26-019262.md","text":"https://secwatch.observer/filing/0001437749-26-019262.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1001316/000143774926019262/0001437749-26-019262-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1001316/000143774926019262/tgtx20260602_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-03T11:35:08.369688+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}